230 related articles for article (PubMed ID: 31553250)
21. Possible clinical indications of ceftobiprole.
Barberán J
Rev Esp Quimioter; 2019 Sep; 32 Suppl 3(Suppl 3):29-33. PubMed ID: 31364339
[TBL] [Abstract][Full Text] [Related]
22. Ceftobiprole medocaril for the treatment of pneumonia.
Hsu WH; Hsu CK; Lai CC
Expert Rev Anti Infect Ther; 2023 Jun; 21(6):551-563. PubMed ID: 37042813
[TBL] [Abstract][Full Text] [Related]
23. A Phase 3, Randomized, Investigator-blinded Trial Comparing Ceftobiprole With a Standard-of-care Cephalosporin, With or Without Vancomycin, for the Treatment of Pneumonia in Pediatric Patients.
Bosheva M; Gujabidze R; Károly É; Nemeth A; Saulay M; Smart JI; Hamed KA
Pediatr Infect Dis J; 2021 Jun; 40(6):e222-e229. PubMed ID: 33480665
[TBL] [Abstract][Full Text] [Related]
24. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Jorgenson MR; DePestel DD; Carver PL
Ann Pharmacother; 2011 Nov; 45(11):1384-98. PubMed ID: 22009993
[TBL] [Abstract][Full Text] [Related]
25. Ceftaroline fosamil (Teflaro) - a new IV cephalosporin.
Med Lett Drugs Ther; 2011 Jan; 53(1356):5-6. PubMed ID: 21252841
[No Abstract] [Full Text] [Related]
26. Clinical profile of ceftobiprole, a novel beta-lactam antibiotic.
Noel GJ
Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():25-9. PubMed ID: 17488373
[TBL] [Abstract][Full Text] [Related]
27. Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA.
Garrison MW; Kawamura NM; Wen MM
Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1087-103. PubMed ID: 23167512
[TBL] [Abstract][Full Text] [Related]
28. New antibiotics for healthcare-associated pneumonia.
Neuner EA; Ritchie DJ; Micek ST
Semin Respir Crit Care Med; 2009 Feb; 30(1):92-101. PubMed ID: 19199191
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of action and antimicrobial activity of ceftobiprole.
Morosini MI; Díez-Aguilar M; Cantón R
Rev Esp Quimioter; 2019 Sep; 32 Suppl 3(Suppl 3):3-10. PubMed ID: 31364335
[TBL] [Abstract][Full Text] [Related]
30. Safety and effectiveness of fifth generation cephalosporins for the treatment of methicillin-resistant staphylococcus aureus bloodstream infections: a narrative review exploring past, present, and future.
Bavaro DF; Belati A; Bussini L; Cento V; Diella L; Gatti M; Saracino A; Pea F; Viale P; Bartoletti M
Expert Opin Drug Saf; 2024 Jan; 23(1):9-36. PubMed ID: 38145925
[TBL] [Abstract][Full Text] [Related]
31. New and emerging treatment of Staphylococcus aureus infections in the hospital setting.
Moreillon P
Clin Microbiol Infect; 2008 Apr; 14 Suppl 3():32-41. PubMed ID: 18318877
[TBL] [Abstract][Full Text] [Related]
32. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation.
Nicholson SC; Welte T; File TM; Strauss RS; Michiels B; Kaul P; Balis D; Arbit D; Amsler K; Noel GJ
Int J Antimicrob Agents; 2012 Mar; 39(3):240-6. PubMed ID: 22230331
[TBL] [Abstract][Full Text] [Related]
33. Ceftaroline fosamil as a potential treatment option for Staphylococcus aureus community-acquired pneumonia in adults.
Welte T; Kantecki M; Stone GG; Hammond J
Int J Antimicrob Agents; 2019 Oct; 54(4):410-422. PubMed ID: 31404620
[TBL] [Abstract][Full Text] [Related]
34. Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types.
Farrell DJ; Flamm RK; Sader HS; Jones RN
Int J Antimicrob Agents; 2014 Apr; 43(4):323-7. PubMed ID: 24411474
[TBL] [Abstract][Full Text] [Related]
35. Ceftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Vidaillac C; Rybak MJ
Pharmacotherapy; 2009 May; 29(5):511-25. PubMed ID: 19397461
[TBL] [Abstract][Full Text] [Related]
36. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
37. How important is methicillin-resistant Staphylococcus aureus as a cause of community-acquired pneumonia and what is best antimicrobial therapy?
Wunderink RG
Infect Dis Clin North Am; 2013 Mar; 27(1):177-88. PubMed ID: 23398873
[TBL] [Abstract][Full Text] [Related]
38. A
Huang H; Gao L; Engelhardt M; Saulay M; Hamed K
Future Microbiol; 2021 Jul; 16():783-796. PubMed ID: 34155899
[TBL] [Abstract][Full Text] [Related]
39. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
Barbour A; Schmidt S; Rand KH; Derendorf H
Int J Antimicrob Agents; 2009 Jul; 34(1):1-7. PubMed ID: 19261449
[TBL] [Abstract][Full Text] [Related]
40. Ceftobripole: Experience in staphylococcal bacteremia.
Soriano A; Morata L
Rev Esp Quimioter; 2019 Sep; 32 Suppl 3(Suppl 3):24-28. PubMed ID: 31364338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
